

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Cystic Fibrosis Mucus Model to Design More Efficient Drug Therapies

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1841487> since 2022-02-17T10:28:27Z

Published version:

DOI:10.1021/acs.molpharmaceut.1c00644

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Cystic fibrosis mucus model to design more efficient drug therapies

Cosmin Butnarusu ^{*a}, Giulia Caron ^a, Daniela Pacheco ^{b,c}, Paola Petrini ^b, Sonja Visentin ^a

^a University of Torino, Department of Molecular Biotechnology and Health Science, Via Quarello15, 10135 Torino, Italy

^b Department of Chemistry, Materials and Chemical Engineering, Giulio Natta-Politecnico di Milano, Italy

^c Bac3Gel Lda, TagusPark – Edificio Inovacao II, Lisbon, Portugal.

*Corresponding author: cosminstefan.butnarusu@unito.it

Keywords: mucus, drugs, permeability, PAMPA, HTS

Abstract

Mucus can represent a strong barrier to tackle for oral or pulmonary administered drugs especially in mucus-related disorders. Still little is known about the molecular properties that mediate the interaction of drugs with mucus. This study uses a pathological cystic fibrosis (CF) mucus model to investigate the impact of mucus over the permeability of 45 commercial drugs. An *in vitro* mucosal surface was recreated by coupling the mucus model to 96-well permeable supports pre-coated with structured layers of phospholipids (PAMPA). The mucus model behaved as an interactive filter as different molecular structures reacted differently to mucus. We also found that permeability can be enhanced when calcium salts are formed. This was confirmed also through the use of cystic fibrosis sputum as a rough ex vivo model of CF mucus. Since development of drugs is characterized by a high rate of failure, the mucus platform could aid to reduce at an early stage the number of poor performer drug candidates preventing them to uselessly reach preclinical trials.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66

1. Introduction


The mucosal surfaces of the human body are constantly exposed to environmental threats. To counteract potential noxious agents, all the wet epithelia are covered with a layer of mucus. Mucus is a dynamic semipermeable network with a heterogeneous composition. It consists of ~95% water and the remaining 5% comprising electrolytes, lipids, DNA fragments and proteins. Maintaining the gel-like properties and keeping together such a huge amount of water requires a strong yet flexible skeleton. The tough job is carried out by mucins. Mucins are long polymeric glycoproteins having high molecular weight, consisting of a peptide backbone to which a huge amount of carbohydrate chains are attached. Such an architecture enables the exchange of nutrients, water, gases and hormones whilst being impermeable to most bacteria and pathogens ^{1,2}.

A delicate balance of mucus production must be achieved as weakening of the mucus barrier makes us more vulnerable to environmental threats. On the contrary, an overproduction or dysfunctional clearance of mucus are hallmarks of the pathogenesis of all the mucus-related pathologies, especially pulmonary diseases³, such as cystic fibrosis (CF) among others. In these disorders, an overexpression of mucins, accumulation of extracellular DNA as well cellular debris, and the persistent presence of bacteria, confers mucus stasis leading to a vicious cycle of infection and inflammation that can be chronically sustained ^{4,5}. In CF and bronchiectasis, sputum production is not only a daily reality, but also a crucial marker for physicians during both stable state and exacerbation used to evaluate disease severity and treatment response. Sputum's reliability as an indicator of disease has led it to being proposed as an important clinical prognostic factor in mucus-related diseases. This has been taken a step further by Murray and colleagues, who explored the utility of sputum color in patients with bronchiectasis by developing a quantitative method that predicts bacterial colonization based on the color of sputum ⁶.

Despite the great advancements in disease management of the last decades, pulmonary failure remains the main cause of morbidity and mortality in patients with CF. The lack of function of the cystic fibrosis transmembrane conductance regulator protein (CFTR) in people with CF, leads to mucus dehydration. As a result, mucus undergoes a reduced clearance, clogging the airways and making it difficult to breath. Physicians have developed advanced clearance techniques (ACTs) based on coughing maneuvers to get rid of the viscous mucus. In addition to the routinely ACTs, CF patients manage their disease by following a regular treatment with medications. The recurrent pulmonary

67 exacerbations are usually treated with both oral and intravenous antibiotics (*i.e.*,
68 aztreonam, tobramycin, levofloxacin), and anti-inflammatory drugs (*i.e.*, high-doses
69 ibuprofen ⁷).

70 Yet, to enter into the systemic circulation, drugs administered by the oral, pulmonary,
71 nasal or rectal routes, need come in contact and subsequently cross the epithelium in
72 order to reach the capillary circuitry in the lamina propria. Thus, effective drugs
73 administered by these routes should harbor the ability to transverse mucus barriers to
74 be pharmacologically active. In the context of cystic fibrosis, the pathological mucus can
75 strongly limit the absorption of drugs that do not exhibit these difficulties under normal
76 physiological conditions. Also, the pathological CF mucus, is characterized by a reduced
77 mesh size (60-300 nm)⁸ with respect to physiological mucus (497-503 nm)⁹. Two main
78 mechanisms are expected to affect drug diffusion through mucus: steric and interactive
79 filtering (Fig. 1). Oligomers of secreted mucins connect with each other creating a
80 complex network that filters molecules bigger than the size of the mesh spacing
81 between mucin fibers ¹⁰ (steric filter). Molecules small enough to penetrate the mucin
82 mesh are subjected to the interactive filter which is mainly governed by the structural
83 complexity of mucins. On the highly glycosylated hydrophilic regions, negative charges
84 are exposed due to the presence of sialic acid. On these substrates, hydrogen bonding
85 and electrostatic interactions can be established with polar and hydrophilic molecules.
86 But not the entire peptide core of mucins is glycosylated; cysteine-rich domains are
87 glycans free and usually folds into hydrophobic regions on which lipophilic molecules
88 can attach. And yet, mucin is just one of the components of mucus. Other substances
89 such as lipids, antimicrobial peptides (defensins, histatins, collectins *etc.*), lytic
90 enzymes (lysozyme) and antibodies (IgA and IgG) are components of mucus as well,
91 and each one of them has the potential to interact with drugs.
92



93
94
95
96
97
98
99

Figure 1. The steric and interactive barriers of mucus. Drugs larger than the mesh spacing between mucin fibers are stacked within mucus because too big to cross the mucus mesh. Similarly, drugs smaller than the mesh but able to interact with mucus components are equally retained by mucus. On the contrary, particles that are small enough and relatively inert to any of the mucus component can freely diffuse through the mucus layer and eventually absorbed.

100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117

The importance of developing *in vitro* models able to model both the biological structure and functions of pulmonary mucus is increasingly gaining awareness in modern drug discovery. Today, the most popular *in vitro* models for assessing permeability/absorption of drugs, are those based on artificial membranes, such as parallel artificial membrane permeability assay (PAMPA)¹¹, systems based on cells, such as Caco-2¹² and MDCK¹³; and systems based on site-specific tissues¹⁴. Notably, none of them takes mucus specifically into account. In the last years, a variety of mucus models have been proposed¹⁵. The proposed models include gastrointestinal mucin-based solutions^{16,17}, reconstituted oral mucus gels¹⁸, multilayered polyelectrolyte films¹⁹, and *in vitro* cell cultures models incorporating airway mucus or mucus-producing cells²⁰. Falavigna *et al.* developed a mucus phospholipid vesicle-based permeation assay that has been used for permeability screening of drugs and formulations²¹.

Recently we developed an *in vitro* mucus model which simplifies mucus complexity by mimicking the chemical composition, structural features and viscoelastic properties of pathological CF mucus²². The viscoelastic property of CF mucus is achieved by taking advantage of the internal gelation of alginate in the presence of calcium ions. Alginate is an extracellular exopolysaccharide component of mucoid *P. aeruginosa*, a hallmark of CF infection, and has been shown to protect bacteria against certain antibiotics as well

118 as escape the immune system ^{23,24}. To reproduce the interactive and steric filters of CF
119 mucus we used commercially available unpurified mucin type III from porcine stomach.
120 One may argue that commercial mucins are different in terms of structure and
121 viscoelastic properties respect to native mucins. Indeed, it has been established that
122 commercial mucins fail to form hydrogels at acidic pH, are only partially purified and
123 are inferior in inhibiting virus infection compared to natively purified mucins obtained
124 in lab ²⁵. However, the purpose of our mucus model is to have an easy to use and easy
125 to reproduce *in vitro* mucus model suitable for average throughput screening (HTS)
126 applications. Thus, even if in lab extracted mucins are qualitatively superior to
127 commercial mucins, the time consuming and expensive procedures of purification,
128 extraction and concentration at laboratory level are not adapted for HTS purposes.
129 In this study, we aimed at expanding the applicability and relevance of our *in vitro* cystic
130 fibrosis pathological mucus model. To reach this aim we addressed the following goals:
131 (i) selected 45 commercially available drugs maximizing physicochemical variability;
132 (ii) performed PAMPA measurements in the absence of mucus and assessed the
133 physicochemical determinants of apparent permeability (P_{app}); (iii) we coupled the
134 developed mucus model with PAMPA to mimic *in vitro* cystic fibrosis airway mucosal
135 surface. The permeability in the presence of mucus was compared with the P_{app}
136 obtained in the absence of mucus; (iv) eventually, permeability with cystic fibrosis
137 sputum was measured to support the conclusion drawn from the *in vitro* model herein
138 presented.
139 Overall, this study highlights the challenging of reproducing *in vitro* the complexity of
140 cystic fibrosis dysfunctional mucus. While PAMPA could be a reasonable model to
141 mimic permeability through cellular membrane, we have shown that it is a too
142 simplistic model to mimic the diffusion across pathological CF mucus. As a first
143 screening tool of poorly permeable molecules, a fully tunable *in vitro* mucus model,
144 easy to reproduce, and mimicking both the composition and the rheological properties
145 of CF mucus, could be of high usefulness in the early drug discovery.

146

147 **2. Experimental section**

148

149 **2.1. Computational Part**

150 The drug SMILES codes were retrieved from DrugBank ²⁶. The csv file of the approved
151 drugs was downloaded from DrugBank (last update on 3 January 2021). The csv file
152 was transformed in xlsx file using Microsoft Excel (v. 16.43). The SMILES of CFTR_{inh-}
153 172, which is a non-commercial drug acting as an inhibitor of the CFTR protein, was

154 retrieved from PubChem²⁷. Molecular properties were calculated with DataWarrior
155 (ver. 5.5.0, openmolecules.org) and include physico-chemical properties, druglikeness
156 related properties, various atom and ring counts, molecular shape, flexibility as well as
157 functional groups (Table S2). The molecular charge at pH 7.4 was retrieved from
158 MarvinSketch (Marvin 20.20, 2020, ChemAxon).
159 The dataset was analyzed with the Principal Component Analysis (PCA) tool
160 implemented in DataWarrior. The correlation matrix of the descriptors was calculated
161 using DataWarrior and represented as a heatmap.

162

163 **2.2. Materials**

164 Mucin from porcine stomach (PGM Type III, bound sialic acid 0.5-1.5%, partially
165 purified powder), sodium salt of alginic acid, calcium carbonate, D-(+)-gluconic acid δ -
166 lactone $\geq 99.0\%$ and sodium chloride used to develop the airway mucus model were all
167 purchased from Merck (Germany). Permeability experiments were carried out on
168 Corning® Gentest™ Pre-coated PAMPA, 353015, USA plates. Millipore® grade water
169 (resistivity: 18.2 M Ω cm at 25 °C) was obtained from an in-house Millipore® system.
170 Acetonitrile, ammonium acetate and DMSO were of the highest available grade and
171 purchased from Sigma Aldrich. The drugs used in this study were all commercially
172 available (Fig. S1). Stock solutions were prepared in DMSO and stored at 4 °C.

173

174 **2.3. Mucus model**

175 The herein used mucus model can be exploited as a platform for drug diffusion either
176 for cystic fibrosis mucus or other mucus-related disorders such as mucus of chronic
177 obstructive pulmonary disease, which unveils its potential for a wide range of
178 applications in drug discovery. The mucus model was prepared as previously described
179 ²². Briefly, a 21 mg/mL alginate sodium salt solution was dissolved in a 16.3 mg/mL
180 NaCl solution, under slow magnetic agitation. In parallel, a 43.7 mg/mL mucin
181 suspension was prepared in mQ water and left under slow agitation over-night. The
182 alginate and mucin solutions were mixed at a 1:4 proportion using two jointed luer-
183 lock syringes. Then, the alginate and mucin suspension were mixed with a suspension
184 of 7 mg/mL CaCO₃ prepared in 16.3 mg/mL NaCl solution. In the last step, a 70 mg/mL
185 GDL solution was freshly prepared in 16.3 mg/mL NaCl and mixed with the previously
186 prepared suspension (alginate, mucin and CaCO₃) at a proportion of 1:6. Finally, 40 μ L
187 of the mucus model were pipetted directly over the PAMPA membrane in the donor
188 compartment, producing a hydrogel of approximately 500 μ m in thickness. The donor
189 plate of the PAMPA was then carefully shaken to uniformly distribute the volume of

190 mucus over the entire well surface and to get rid of any air bubbles. Afterwards, the
191 mucus within the plate was left to crosslink for 24 h before the addition of drug
192 solutions. Throughout the time course of the permeability experiment, the CF mucus
193 model remained stable with respect to weight and thickness variations. In fact, we
194 previously determined that after 6h of incubation in an aqueous medium, mucus
195 undergoes a thickness variation below 10% which was considered acceptable for our
196 experimental purpose²².

197

198 **2.4. PAMPA assay**

199 The apparent permeability (P_{app}) and the effect of mucus on permeability were
200 experimentally determined through PAMPA and mucus-PAMPA assays, respectively.
201 Stock solutions of all drugs were prepared in DMSO at a concentration of 10 mg/mL.
202 Donor solutions of drugs were prepared in PBS (10 mM, pH 7.4, 5% DMSO) at a
203 concentration between 100 to 500 μ M, depending on the drugs' specific solubility. Each
204 donor well was filled with 200 μ L of drug solution, while the acceptor wells were filled
205 with 300 μ L of PBS. The donor plate was then placed on top of the acceptor plate, so the
206 artificial membrane was in contact with the buffer solution below. A lid was placed on
207 top of the donor plate and the whole PAMPA plate was incubated at room temperature
208 for 5 h. At the end of the incubation period, the plates were separated, and the volume
209 of the acceptor wells was collected. Concentrations of drugs in each acceptor well were
210 quantified either by HPLC-UV or HPLC-MS. The apparent permeability coefficient (P_{app})
211 was expressed using equation 1 derived from Fick's law²⁸ for steady state conditions:

$$212 \quad P_{app} = \frac{dQ/dt}{C_0 \times A} \quad (Eq. 1)$$

213 where dQ is the quantity of drug expressed as moles permeated into acceptor
214 compartment at time t (18,000 sec), C_0 is the initial concentration in the donor well and
215 A is the area of the well membrane (0.3 cm²). The P_{app} was used as an average of all the
216 measures.

217 The same PAMPA experimental setup was adopted when assessing the effect of
218 individual components of mucus. In particular, we evaluated how the PGM, the NaCl,
219 the alginate hydrogel and calcium impact on permeability. For this purpose, the passive
220 diffusion was measured in the presence of each one of these chemicals. Each of which,
221 were individually added in the donor compartment of the PAMPA. In brief, 40 μ L of the
222 alginate gel were deposited over the phospholipid membrane of the donor
223 compartment prior the addition of drug solution. The influence of PGM was assessed by
224 filling the donors with a suspension of drug containing 4.16 mg/mL of PGM (the PGM
225 concentration donor compartment). Similarly, drug donor solutions containing 1.67

226 mM CaCl₂ or 20 mM NaCl were used when investigating the impact of calcium and NaCl
227 over permeability.

228

229 **2.5. Cystic fibrosis sputum**

230 Sputum collected from cystic fibrosis patients was used as a model of complex
231 biological matrix representative of CF mucus. We measured the permeability of some
232 of the drugs of our dataset using the CF sputum – PAMPA system and compared the
233 results with the permeability obtained in the presence of our mucus model. Sputum
234 samples were a kind concession of Prof. A. Ghigo from the Department of Molecular
235 Biotechnology of University of Turin. Spontaneously expectorated sputum was
236 collected into sterile containers and was processed as described by Oriano *et al.* ²⁹.
237 Briefly, samples were processed getting first rid of saliva. Then, samples were diluted
238 8x in PBS, vortexed until sputum dissolution and centrifuged for 15 min at 3000 g. Forty
239 µL of sputum were deposited over the PAMPA membrane in the bottom of the top plate,
240 and eventually 200 µL of drug solution were inserted over the layer of CF sputum, while
241 300 µL of PBS were inserted into the bottom plate of the PAMPA. The two plates were
242 coupled and incubated for 5h. At the end of the 5h the plates were splitted and the
243 amount of drug diffused into the bottom plate was quantified. Similarly, to test the effect
244 of calcium over the permeability of the drug, we formed drug-calcium complexes by
245 dissolving the drug into PBS containing calcium at the same concentration present in
246 the cystic fibrosis mucus model. The permeability of calcium-drug complexes was
247 measured through the CF sputum PAMPA as previously described.

248

249 **2.6. Quantification**

250 All compounds, except ebselen, benzoic acid and 3-aminophenol, were analyzed and
251 quantified by HPLC-MS/MS using a Varian HPLC equipped with a 410 autosampler and
252 an Ascentis C18 column (10 cm x 2.1 mm, 3 µm). Gradient mobile phases composed of
253 acetonitrile and water 0.1% formic acid or ammonium acetate 5 mM pH 6.6 as organic
254 and aqueous phase respectively were pumped at a flow rate of 200 µL/min. A flow of
255 200 µL/min and an injection volume of 10 µL were used. Compounds were detected on
256 a Varian 320 MS TQ Mass Spectrometer equipped with an electrospray ionization (ESI)
257 source operating in positive or negative mode, depending on drugs' method. The
258 detector was used in multiple reaction monitoring (MRM) mode and the transitions of
259 each drug are reported in Table S1.

260 Ebselen, benzoic acid and 3-aminophenol were quantified on a HPLC Varian ProStar
261 equipped with a 410 autosampler and a PDA 335 LC Detector. The analysis was

262 conducted on a IAM column (Regis, 10 cm x 4.6 cm 10 μm packing 300 \AA pore size)
263 using ammonium acetate and acetonitrile as aqueous and organic mobile phase,
264 respectively. The flow rate was 1 mL/min.

265

266 **2.7. Statistical analysis**

267 A minimum of 4 replicates were conducted for each compound on each experimental
268 method (with or without the mucus model), some of whom repeated also on different
269 PAMPA plates. Results are expressed as mean \pm SD. Student's t-test was applied to
270 detect statistical significance between the permeability recorded with and without
271 mucus. A $p < 0.05$ was considered to be a statistically significant difference.

272

273 **3. Results and discussion**

274


275 **3.1. Dataset selection: assessment of chemical heterogeneity**

276 We included in our dataset a number of anti-inflammatory (ibuprofen, dexamethasone)
277 and antibacterial drugs (tobramycin, ceftazidime, aztreonam, ciprofloxacin,
278 tetracycline) commonly employed in the cystic fibrosis therapy regimes. To properly
279 evaluate the performances of our CF mucus model, we expanded the dataset up to 45
280 compounds considering it a reasonable number of drugs to be investigated, with good
281 variability in terms of chemical properties (see below).

282 To assess the distribution of our dataset within the entire drug chemical space, at first,
283 we downloaded the DrugBank database of approved drugs. From DrugBank's database
284 we retrieved the SMILES code for each compound and used them to calculate molecular
285 descriptors (see Methods, Table S2). Using drugs as observations and the selected
286 molecular descriptors as variables, we then computed a principal component analysis
287 (PCA). The drugs within our dataset are small molecules therefore, focus was pointed
288 on compounds of total molecular weight $< 1,000$ Da (yellow dots in Fig. 2A). The
289 variance explained by PC1 and PC2 using 30 molecular descriptors is about 60%. In the
290 score plot defined by PC1 and PC2 is possible to appreciate a good distribution of the
291 tested drugs within the chemical space (red dots in Fig 2A).

292 To assess chemical variability within our dataset we also evaluated the Lipinski's rule
293 of five (Ro5) molecular descriptors distribution (the number of the hydrogen bond
294 donors (HBD), the number of the hydrogen bond acceptors (HBA), the molecular mass
295 (MW), and the octanol-water partition coefficient (LogP)). Figure 2B shows that all the
296 descriptors categories are well represented by the dataset,

297



298

299

300

301

302

303

304

Figure 2. (A) Distribution of the tested drugs (red dots) within the DrugBank database of approved drugs (yellow dots) having total molecular weight ≤ 1000 Da. (B) Classification and distribution based on Lipinski's rule of five (B). Compounds that violate the Ro5 for each molecular descriptor are represented by the red bars.

305

3.2. Validation of the permeability setup to measure P_{app}

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

Before evaluating the effect of mucus on drug permeability, we determined and validated permeability in the absence of mucus through an artificial cellular membrane since our method differs from the standard PAMPA protocol. In fact, in our setup (modified setup), mucus was placed over the PAMPA membrane (a filter plate pre-coated with structured layers of phospholipids), in the top well as is the only way to have a physical support that can sustain mucus. Thus, diffusion takes place from the top to bottom well and drug has been quantified only in the acceptor compartment (bottom well).


Data obtained with our original set-up (Table 1) were firstly validated using a subset of compounds taken from the paper of Chen et al.,³⁰ (Table S3 and Fig. S2) using the same artificial membrane ($r^2=0.610$, Fig. S2). Notably, compounds as propranolol and caffeine known for being high permeable^{31,32} could clearly be discriminated from low permeable compounds.

Then we determined which molecular descriptors mostly govern permeability in our system. To do that a correlation matrix between apparent permeability (P_{app}) and a pool of molecular descriptors (Fig. S3 and Methods) were calculated. The highest correlation ($r^2 = 0.303$) was found to exist with topological polar surface area (TPSA, the surface sum over all polar atoms or molecules, mainly oxygen and nitrogen, also including their attached hydrogen atoms) and in minor extent with hydrogen bond donor and acceptor groups (HBD and HBA). In particular, the higher the TPSA, the lower the P_{app} . This is in line with the literature³³ and again confirms the reliability of our system.

326 Finally, we verified whether TPSA can distinguish high from low permeable
327 compounds. Although a definitive threshold is missing, in the standard PAMPA setup
328 the P_{app} value for distinguishing low from highly permeable compounds is frequently
329 set at 1.5×10^{-6} cm/s³⁰. However, in a modified setup (diffusion from the top to the
330 bottom well) the permeability threshold is higher^{34,35}. Here we used 4×10^{-6} cm/s and
331 1×10^{-6} cm/s to distinguish high, medium and low permeable molecules. Figure 3B
332 shows that TPSA values of 140 \AA^2 ³⁶, and of 75 \AA^2 ^{37,38} are able to predict permeability
333 class of the investigated dataset.

334 In addition to the discrimination based on the total polar surface area, we plotted the
335 high and low permeable compounds in the chemical space based on their chemical
336 properties. For this purpose, we computed a principal component analysis using as
337 variables the molecular descriptors calculated from DataWarrior. Indeed, we can
338 observe a good separation of the two groups on the first principal component (See Fig.
339 S4 A-C).

340



341

342

Figure 3. Classification in high and low permeable compounds (A) of the tested drugs based on the determined apparent permeability (P_{app}) Dataset grouping within permeability categories (B): permeability classification: green = high, yellow = medium, red = low. The P_{app} threshold high-medium and medium-low permeable compounds was set at 4 and 1×10^{-6} , respectively. TPSA threshold between high-medium and medium-low permeable compounds was set at 75 and 140 \AA^2 , respectively. The number beneath each dot refers to drug name (see Fig. S1 and Table 2).

343

344

345

346

347

348

349

Overall, we validated the goodness of the experimentally determined P_{app} in the absence of mucus and confirmed that the P_{app} values can be used as benchmark when assessing the effect of mucus in the mucus-PAMPA system.

350


351

352

353
354
355
356
357
358
359
360

3.3. Permeation studies in the presence of a mucus model

The mucus model was adapted to the PAMPA plate by directly pipetting it on top of the phospholipid membrane in the donor compartment. As all the wet epithelia of the human body are covered by mucus, drugs administered by oral or pulmonary routes have to cross both the mucus layer and the cellular membrane to be absorbed, and thus to be effective. With our adapted mucus-PAMPA system we are expecting to be able to mimic *in vitro* the interface at mucosal surfaces. (Fig. 4).



361
362
363
364
365
366
367
368
369
370
371
372
373
374
375

Figure 4. Comparison between PAMPA and mucus-PAMPA system. On top the upper view of the PAMPA wells, on the bottom the lateral view of the donor and acceptor compartments. Dashed lines highlight the mucus layer and the phospholipid membrane (PM).

The effect of mucus was measured in terms of variations of permeability and was considered statistically significant only if the p -value between the means of the two groups (PAMPA and mucus-PAMPA) was <0.05 . A summary of the P_{app} with and without mucus is reported in Table 1, while the detail of each drug tested is reported in SI (Fig. S6).

Table 1. Summary of the P_{app} recorded on PAMPA and the effect the mucus model played over permeability with the respective P_{app} variations. The terms *increased* / *decreased* are used only if the difference on permeability is statistically significant. Student's t-test was applied to detect statistical significance between

376
377
378

the permeability recorded with and without mucus. A $p < 0.05$ was considered to be a statistically significant difference.


Nr	Compound	MW (g/mol)	Lipophilicity	P_{app} PAMPA (\pm SD) $\times 10^{-6}$ [cm/s]	P_{app} Mucus-PAMPA (\pm SD) $\times 10^{-6}$ [cm/s]	Effect of mucus on P_{app}
1	Propranolol	259.3	medium	12.56 (\pm 2.9)	2.84 (\pm 1.4)	Decreased (-1)
5	Ebselen	274.2	low	4.01 (\pm 0.6)	1.82 (\pm 0.8)	Decreased (-1)
8	Oseltamivir	312.4	medium	1.30 (\pm 0.3)	0.32 (\pm 0.1)	Decreased (-1)
11	Umifenovir	477.4	medium	1.03 (\pm 0.1)	0.18 (\pm 0.0)	Decreased (-1)
12	Zanamivir	332.3	medium	0.42 (\pm 0.2)	0.02 (\pm 0.0)	Decreased (-1)
13	Levofloxacin	361.4	low	5.94 (\pm 2.7)	0.00 (\pm 0.0)	Decreased (-1)
14	CFTRinh-172	409.4	medium	7.35 (\pm 2.9)	3.84 (\pm 1.2)	Decreased (-1)
15	Verapamil	454.6	low	8.57 (\pm 2.0)	0.53 (\pm 0.5)	Decreased (-1)
16	3-aminophenol	109.1	low	8.28 (\pm 1.4)	0.74 (\pm 0.6)	Decreased (-1)
17	Amlodipine	408.9	medium	6.60 (\pm 1.9)	0.00 (\pm 0.0)	Decreased (-1)
18	Amitriptyline	277.4	high	5.80 (\pm 1.2)	0.00 (\pm 0.0)	Decreased (-1)
19	Procaine	236.3	low	4.00 (\pm 1.0)	0.00 (\pm 0.0)	Decreased (-1)
20	Caffeine	194.2	low	12.70 (\pm 3.5)	6.43 (\pm 4.2)	Decreased (-1)
25	Tetracycline	444.4	high	1.22 (\pm 1.0)	0.00 (\pm 0.0)	Decreased (-1)
26	Ritonavir	721.0	high	1.60 (\pm 0.4)	0.61 (\pm 0.2)	Decreased (-1)
31	Salbutamol	239.3	low	0.04 (\pm 0.0)	0.01 (\pm 0.0)	Decreased (-1)
34	Lumacaftor	452.4	medium	6.64 (\pm 0.8)	5.40 (\pm 0.3)	Decreased (-1)
36	Lidocaine	234.3	high	9.47 (\pm 0.3)	0.05 (\pm 0.1)	Decreased (-1)
38	GDCA	449.6	medium	0.76 (\pm 0.3)	0.22 (\pm 0.3)	Decreased (-1)
42	Quinine	324.4	low	9.54 (\pm 1.0)	6.66 (\pm 0.6)	Decreased (-1)
3	Camostat	398.4	medium	3.04 (\pm 1.3)	3.28 (\pm 2.9)	None (0)
4	Dexamethasone	392.5	medium	0.85 (\pm 0.4)	0.46 (\pm 0.4)	None (0)
6	Favipiravir	157.1	high	2.44 (\pm 1.1)	3.17 (\pm 1.3)	None (0)
7	Indinavir	613.8	low	1.22 (\pm 0.3)	0.94 (\pm 0.7)	None (0)
9	Remdesivir	602.6	low	1.86 (\pm 1.6)	1.63 (\pm 1.5)	None (0)
10	Saquinavir	670.9	high	0.08 (\pm 0.1)	0.10 (\pm 0.1)	None (0)
24	Ampicillin	349.4	high	2.29 (\pm 0.6)	1.34 (\pm 0.7)	None (0)
28	Ceftazidime	546.6	low	0.93 (\pm 0.5)	1.14 (\pm 1.0)	None (0)
29	Ciprofloxacin	331.3	low	0.54 (\pm 0.3)	0.31 (\pm 0.3)	None (0)
30	Rifampicin	823.0	high	0.61 (\pm 0.4)	0.19 (\pm 0.1)	None (0)
32	Aztreonam	435.4	low	2.45 (\pm 1.5)	1.64 (\pm 0.6)	None (0)
33	Cefuroxime	424.4	low	0.87 (\pm 0.7)	0.16 (\pm 0.2)	None (0)
35	Valsartan	435.5	low	0.56 (\pm 0.5)	0.44 (\pm 0.5)	None (0)
37	TUDCA	499.7	high	0.17 (\pm 0.2)	0.04 (\pm 0.1)	None (0)
39	Tobramycin	467.5	high	0.19 (\pm 0.0)	0.25 (\pm 0.1)	None (0)
40	Ibuprofen	206.3	medium	9.09 (\pm 1.4)	10.33 (\pm 1.2)	None (0)
45	Antipyrine	188.2	medium	5.75 (\pm 1.7)	6.19 (\pm 2.6)	None (0)
2	Baricitinib	371.4	high	0.99 (\pm 0.5)	2.68 (\pm 2.1)	Increased (+1)
21	Naproxen	230.3	low	9.57 (\pm 3.9)	22.02 (\pm 6.1)	Increased (+1)
22	Piroxicam	331.4	high	3.15 (\pm 0.8)	6.63 (\pm 0.1)	Increased (+1)
23	Diclofenac	296.2	medium	4.03 (\pm 0.2)	5.06 (\pm 0.1)	Increased (+1)
27	Indomethacin	357.8	medium	1.32 (\pm 0.3)	2.54 (\pm 0.9)	Increased (+1)
41	Acetaminophen	151.2	medium	0.99 (\pm 0.1)	6.22 (\pm 0.9)	Increased (+1)
43	Benzoic acid	122.1	medium	4.06 (\pm 0.9)	9.91 (\pm 0.9)	Increased (+1)
44	Ketoprofen	254.3	low	4.04 (\pm 0.7)	9.24 (\pm 1.2)	Increased (+1)

379
380
381
382
383
384
385
386
387

Three kinds of mucus-induced effects were observed (Table 1 and Fig. 5A): a) in the presence of mucus, 44% of drugs showed a decreased permeability, b) 38% had no statistically significant variation, and c) 18% had an increased permeability. Among the compounds which diffusion was reduced by mucus, we cannot outline any dependency on drugs lipophilicity. In fact, mucus reduced the permeability of both hydrophilic and lipophilic drugs which is in agreement with what found by Boegh *et al.*,¹⁸ using a biosimilar mucus on Caco-2 cells, and Falavigna *et al.*,²¹ with a mucin-PVPA system.

388 Data suggests that the CF pathological mucus model did not act as a mere physical
389 barrier. It behaves as an interactive filter as different structures interacted differently
390 with mucus. This can be attributed to low affinity interactions taking place during the
391 diffusion process across the mucus layer and is mostly dependent on the structure of
392 mucins. In fact, due to the complex architecture of mucins, hydrophobic drugs can be
393 retained by the naked domains of the peptide core of mucin, while hydrophilic drugs
394 can entangle with the branched oligosaccharides. In addition to the interactive filter
395 orchestrated by mucins through hydrophobic, electrostatic and hydrogen bonding
396 interactions, mucins can hinder the diffusion of xenobiotics also through a size filtering
397 mechanism dependent on the mucin mesh. To estimate the mesh size of our mucus
398 model we applied the generalized Maxwell model (GMM) as described in our previous
399 work²². The estimated mesh size was 54.7 ± 5.35 nm which is in good agreement with
400 what reported in the literature for pathological mucus. Considering that our dataset is
401 composed of only small molecules, thus much smaller than the mesh of our mucus
402 model, we think the steric filter had a minor impact on drug diffusion.
403 Once we had assessed the effect that mucus plays on the P_{app} (*i.e.*, decreased, no effect,
404 increased) of each compound, we then wanted to quantitatively compute the activity of
405 mucus. Thus, we assigned numerical values to each effect, particularly -1, 0, +1 when
406 the permeability was decreased, unvaried and increased, respectively. The effect of
407 mucus over permeability varies without any apparent relation to any of the molecular
408 descriptors selected, as shown by the correlation matrix (Fig. S3), In fact, the relation
409 between the P_{app} and TPSA registered in the absence of mucus does not hold true
410 anymore. If we previously could correctly predict the permeability of almost 80% of the
411 tested compounds, after the addition of mucus we see that only 53% of the molecules
412 have their permeability correctly predicted (Fig. 5B). For instance, amitriptyline
413 (compound nr. 18) in the absence of mucus belongs to the high permeable group as it
414 has low TPSA and high P_{app} ; in contrast, the presence of mucus strongly decreases its
415 permeability. Amitriptyline is a highly lipophilic drug though being positively charged
416 at pH 7.4. Such a reduction of permeability that we observe, may be the result of a
417 combined retention due to interactions with the lipophilic domains and the negatively
418 charged glycans of mucin. As amitriptyline, many other drugs have their permeability
419 decreased (see Table 1 and Fig. 5).
420 With the drug diffusion studies on the mucus-PAMPA system we show that the
421 pathologic cystic fibrosis mucus model can strongly influence the permeability of drugs.
422 Theoretically, if the observed effects would have been similar for all compounds, one
423 could reasonably state that the rate-limiting factor could be the longer diffusive

424 pathway when in the presence of mucus. Though, this hypothesis should be discarded
 425 as we have found that for some drugs the presence of the pathological mucus model
 426 may increase permeability. These results are discussed in the next session.
 427



428
 429 **Figure 5.** The impact of mucus over permeability. (A) The permeability recorded in the presence of mucus.
 430 (B) Grouping within permeability categories of the 45 compounds tested (permeability classification: green
 431 = high, yellow = medium, red = low). The P_{app} threshold of high-medium and medium-low is set at 4 and 1 ×
 432 10⁻⁶, respectively. TPSA threshold of high-medium and medium-low is set at 75 and 140 Å², respectively. The
 433 number beneath each dot refers to drug name (see Fig. S1 and Table 2). As an example, focus is pointed on
 434 the variation of permeability of amitriptyline (nr 18, blue dot) in the absence and presence of mucus.
 435

436 **3.4. On the increased permeability in the presence of pathological mucus**


437 We expected the mucus model to reduce or have no effect on the permeability of drugs.
438 Figure 5A clearly reports that some of the compounds we tested (such as naproxen)
439 presented a higher permeability in the presence of mucus than in its absence. Among
440 the tested drugs, 18% (baricitinib, naproxen, piroxicam, diclofenac, indomethacin,
441 acetaminophen, benzoic acid, ketoprofen) had a significant increase of permeability in
442 the presence of mucus. In respect to the entire dataset, the increased-permeability
443 group share some chemical-physical properties; they are relatively small molecules
444 (MW < 380 Da, Total Surface Area < 270 Å²), lipophilic (cLogP > 1), have medium-low
445 polarity (PSA < 130 Å²), and 6 out of 8 are negatively charged at pH 7.4.

446

447 **3.4.1. The role of the mucus components in the enhancement of**
448 **permeability**

449 To isolate the driving force of the increased diffusion rate observed in the presence of
450 our mucus model, we disassembled the mucus and measured the permeability of
451 naproxen in the presence of each one of the components of mucus. For this purpose, we
452 selected naproxen as a model drug as it is the most remarkable compound for which
453 the permeability increases with mucus (Fig S6). The main components of our mucus
454 model are PGM which is used to mimic the composition of CF mucus; alginate because
455 it is produced by mucoid *P. aeruginosa* infecting the CF mucus; CaCO₃ used to crosslink
456 alginate, and NaCl necessary to reproduce the salinity of CF mucus. Thus, we performed
457 a PAMPA assay where naproxen solutions were prepared in PBS buffer containing
458 either PGM, or NaCl or calcium in the same concentrations used in the mucus model. In
459 the case of the alginate gel, it was deposited on the bottom of the top compartment of
460 the PAMPA the day before the experiment to allow alginate to crosslink. (top of Fig. 6).
461 We observed that while the diffusion rate in the presence of PGM or NaCl did not
462 undergo major variations, in the other two systems (*i.e.*, the alginate gel and CaCl₂) a
463 net increase of permeability was obtained. It is noteworthy to remind that the alginate
464 gel contains calcium as it is necessary to crosslink the alginate solution hence, to form
465 the hydrogel matrix. The most probable scenario explaining such an activity could rely
466 on ion-pairing as it is known that Ca²⁺ ions have a strong affinity for O, N or F atoms
467 because the metal act as Lewis acid and thus form complexes with many ligands³⁹. The
468 binding of calcium ions is highly selective and can form asymmetric complexes that
469 consist of a large radius.

470




471
472
473
474

Figure 6. (A) The experimental setup used to isolate the effect of each one of the components of mucus. (B) the permeability of naproxen recorded in the presence of individual components of mucus.

475 3.4.2. The role of calcium

476 Once we isolated Ca^{2+} as the reason for the increased permeability, we then wanted to
477 understand if this phenomenon is dependent on the negative charge borne by some of
478 the drugs. Tests were repeated with ketoprofen and indomethacin as anions on which
479 mucus increased their respective permeabilities, as well as $\text{CFTR}_{\text{inh-172}}$ and cefuroxime
480 as anions with reduced and unvaried permeability (negative controls) in the presence
481 of mucus, respectively. For naproxen, ketoprofen and indomethacin, permeability rises
482 in presence of the alginate hydrogel and gets even higher in presence of the only CaCl_2
483 (Fig. 7A). It has been reported that these three drugs and other non-steroidal anti-
484 inflammatory agents (NSAIDs) can form complexes with calcium³⁹⁻⁴¹. Interestingly,
485 Ogiso and colleagues reports that the absorption of indomethacin calcium salt on rat
486 abdominal skin is significantly higher than that from indomethacin alone⁴¹. When
487 forming complexes with calcium, naproxen, ketoprofen and indomethacin are
488 neutralized; they shift from a negatively charged form to exhibiting no relative charge.

489 The neutralization implies a decrease of polarity in favor of lipophilicity which we think
 490 it actually favors the diffusion through the artificial phospholipid membrane of PAMPA
 491 (Fig. 7B). It should be noted, when drug-calcium complexes are formed, the molecular
 492 descriptors are completely different from that of the free drugs and cannot be easily
 493 calculated. In addition, the higher permeability observed with CaCl₂ could be due to
 494 larger availability of free Ca²⁺ in solution. In fact, in the system containing alginate,
 495 despite having the same Ca²⁺ concentration, part of it is not available because of the ion
 496 crosslinking with alginate. On the contrary, we observe that the permeability of
 497 CFTR_{inh}-172 and cefuroxime is not influenced by the presence of calcium, even though
 498 if they are also considered anionic drugs.
 499 Overall, we hypothesized that drug-calcium salts have higher passive diffusion rates
 500 through the PAMPA phospholipid artificial membrane with respect to the not-
 501 complexed drug. However, the formation of calcium salts is not merely dependent on
 502 the negative charge as not all the anionic drugs included in the dataset enhanced
 503 permeability.
 504



505
 506

507 **Figure 7.** The effect of calcium over the permeability of some anions at pH 7.4. (A) Naproxen, ketoprofen and
508 indomethacin have higher diffusion rates when calcium is present. CFTR_{inh}-172 and cefuroxime do not
509 undergo permeability variations in the presence of calcium. Two-way ANOVA comparing each group mean
510 with the mean of each other group was used to compute statistical analysis. (B) Schematic representation of
511 the calcium-naproxen complex and the passive diffusive mechanism through mucus-PAMPA system.
512


513 **3.4.3. CF patient sputum validation**

514 In the next step we wanted to understand if the results recorded in the presence of our
515 mucus model can be reproduced using a more complex biological matrix to mimic CF
516 sputum. For this purpose, we employed CF sputum as it is often considered a rough *ex*
517 *vivo* model of CF mucus, and we measured the permeability of naproxen, ketoprofen
518 and indomethacin. In fact, a hallmark of diseases such as CF, COPD and bronchiectasis
519 is the excessive production of sputum. As a consequence of the altered physico-
520 chemical properties, the diseased sputum contains higher concentrations of
521 inflammatory mediators, lytic enzymes (*i.e.*, neutrophil elastase) and bacterial
522 colonization. However, due to the high variability among patients, which depends on
523 the diseases stage, the measurements performed with CF sputum may have a low
524 reproducibility.

525 Given the high concentration of calcium in our mucus model we wanted to find out if
526 the permeability of some negatively charged drugs results overestimated when using
527 the mucus model developed by us. As expected, in the presence of the CF sputum the
528 permeability of naproxen, ketoprofen and indomethacin was decreased, even though
529 the variation was not statistically significant (FIG. 8A). Such a reduction could be the
530 result of interactions with neutrophil elastase and proteases also present at high
531 concentrations in the CF sputum. Mandel *et al.*⁴², reported higher concentrations of
532 calcium ($136 \pm 33 \mu\text{g/mL}$) in submaxillary saliva of CF patients with respect to healthy
533 people ($71 \pm 19 \mu\text{g/mL}$). Based on these values, we can estimate almost a 10x higher
534 concentration of calcium in our model than that of the *in vivo* scenario. Therefore, we
535 can speculate that the permeability of some negatively charged drugs might be
536 overestimated with our CF mucus model.

537 Despite this, we establish evidence indicating that some negatively charged drugs can
538 form calcium-drug salts which have higher diffusion rates on PAMPA respect to the free
539 drugs. In terms of permeability, these salts might be less affected by the barrier effect
540 of mucus. Thus, we wondered if this mechanism can be exploited to increase the
541 permeability of naproxen, ketoprofen and indomethacin through CF sputum. For this
542 purpose, we repeated the permeability test through CF sputum, this time suspending
543 the drugs into PBS containing calcium. As can be seen from Fig. 8B, the permeability of

544 all of the three drugs was significantly higher for the samples containing calcium. This
 545 is likely a consequence of the formation of calcium complexes which increased more
 546 than twice the permeability of the drugs through CF sputum.
 547 Even though the concentration of calcium in the CF mucus is reported to be lower than
 548 that of our mucus model, it is still clear the impact that calcium can play on permeability.
 549 Drug calcium salts might have better biological activities and should be considered
 550 when formulating drugs. For instance, high-dose ibuprofen taken constantly for years
 551 has shown to significantly reduce the progression of the lung disease in cystic fibrosis⁷.
 552 It would be interesting to investigate if better health outcomes could be reached using
 553 a calcium formulation.
 554



555
 556 Figure 8. The effect of calcium over the permeability of naproxen, ketoprofen and indomethacin in the
 557 presence of cystic fibrosis (CF) sputum. (A) The permeability of the three drugs measured on the CF sputum
 558 - PAMPA system and compared with PAMPA (CTRL). (B) The increase of permeability through the CF sputum
 559 - PAMPA after the formation of calcium-drug complexes. Two way ANOVA was used to compute statistical
 560 analysis.
 561

562 Conclusions

563
 564 Here we used an *in vitro* pathological cystic fibrosis mucus model to explore how it can
 565 impact over permeability of a dataset of 45 compounds. Overall, our data suggest that
 566 the activity of mucus is complex to predict. Determining the specific effects limiting the
 567 permeability of drugs through mucus was out of the scope of this work. Yet, it was found
 568 that the mucus was not only a physical barrier for the permeability of drugs but also
 569 behaved as a dynamic filter as well. The permeability of most of the compounds was
 570 reduced, whilst others have not been affected by the barriers of mucus. A poor

571 correlation of the effect of mucus on permeability was found for all of the selected
572 molecular descriptors. These findings represent an additional evidence of the further
573 need for reliable *in vitro* mucus models to be used for drug screening, especially in
574 mucus related disorders.

575 We also ascertained that calcium, which is one of the components of our mucus model,
576 enhanced the permeability of a small group of drugs. This was most likely the result of
577 the complexation with the drug. The observed increased-permeability effect induced
578 by calcium was also achieved also through cystic fibrosis sputum, further highlighting
579 the potential to use drugs as calcium salts to pursue higher absorption rates *in vivo*.
580 Additionally, calcium-based formulations could offer new potentialities also for the
581 repositioning of the current therapies.

582

583 **Declaration of competing interests**

584

585 The authors declare that they have no known competing financial interests or personal
586 relationships that could have appeared to influence the work reported in this paper.

587

588 **Acknowledgements**

589

590 The authors acknowledge the financial support from the University of Torino (Ricerca
591 Locale ex-60%, Bando 2020).

592

593 **Abbreviations**

594

595 CF: cystic fibrosis

596 COPD: chronic obstructive pulmonary disease

597 PAMPA: parallel artificial membrane permeability assay.

598 PBS: phosphate buffer saline

599 HPLC-MS: high-pressure liquid chromatography – mass spectrometry

600 DMSO: dimethyl sulfoxide

601 P_{app} : apparent permeability

602 GDL: D-(+)-gluconic acid δ -lactone

603 MRM: multiple reaction monitoring

604 PCA: principal component analysis

605 Ro5: Lipinski rule of five

606 NSAID: non-steroidal anti-inflammatory drug

607

608 **References**

609

- 610 (1) Murgia, X.; Loretz, B.; Hartwig, O.; Hittinger, M.; Lehr, C. The Role of Mucus on
611 Drug Transport and Its Potential to Affect Therapeutic Outcomes. *Adv. Drug*
612 *Deliv. Rev.* **2018**, *124*, 82–97. <https://doi.org/10.1016/j.addr.2017.10.009>.
- 613 (2) Cone, R. A. Barrier Properties of Mucus. *Adv. Drug Deliv. Rev.* **2009**, *61* (2), 75–
614 85. <https://doi.org/10.1016/j.addr.2008.09.008>.
- 615 (3) Fahy, J. V.; Dickey, B. F. Airway Mucus Function and Dysfunction. *N. Engl. J.*
616 *Med.* **2010**, *363* (23), 2233–2247. <https://doi.org/10.1056/nejmra0910061>.
- 617 (4) Mitri, C.; Xu, Z.; Bardin, P.; Corvol, H.; Touqui, L.; Tabary, O. Novel Anti-
618 Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of
619 Molecular Targets and Design of Innovative Therapies. *Front. Pharmacol.*
620 **2020**, *11* (July), 1–25. <https://doi.org/10.3389/fphar.2020.01096>.
- 621 (5) Meldrum, O. W.; Chotirmall, S. H. Mucus, Microbiomes and Pulmonary Disease.
622 *Biomedicines* **2021**, *9* (6), 675.
623 <https://doi.org/10.3390/biomedicines9060675>.
- 624 (6) Murray, M. P.; Pentland, J. L.; Turnbull, K.; MacQuarrie, S.; Hill, A. T. Sputum
625 Colour: A Useful Clinical Tool in Non-Cystic Fibrosis Bronchiectasis. *Eur.*
626 *Respir. J.* **2008**, *34* (2), 361–364.
627 <https://doi.org/10.1183/09031936.00163208>.
- 628 (7) Konstan, M. W.; Byard, P. J.; Hoppel, C. L.; Davis, P. B. Effect of High-Dose
629 Ibuprofen in Patients with Cystic Fibrosis. *N. Engl. J. Med.* **1995**, *332* (13), 848–
630 854. <https://doi.org/10.1056/nejm199503303321303>.
- 631 (8) Suk, J. S.; Lai, S. K.; Wang, Y. Y.; Ensign, L. M.; Zeitlin, P. L.; Boyle, M. P.; Hanes, J.
632 The Penetration of Fresh Undiluted Sputum Expecterated by Cystic Fibrosis
633 Patients by Non-Adhesive Polymer Nanoparticles. *Biomaterials* **2009**, *30* (13),
634 2591–2597. <https://doi.org/10.1016/j.biomaterials.2008.12.076>.
- 635 (9) Yu, T.; Chisholm, J.; Choi, W. J.; Anonuevo, A.; Pulicare, S.; Zhong, W.; Chen, M.;
636 Fridley, C.; Lai, S. K.; Ensign, L. M.; Suk, J. S.; Hanes, J. Mucus-Penetrating
637 Nanosuspensions for Enhanced Delivery of Poorly Soluble Drugs to Mucosal
638 Surfaces. *Adv. Healthc. Mater.* **2016**, *5* (21), 2745–2750.
639 <https://doi.org/10.1002/adhm.201600599>.
- 640 (10) Boegh, M.; Nielsen, H. M. Mucus as a Barrier to Drug Delivery - Understanding
641 and Mimicking the Barrier Properties. *Basic Clin. Pharmacol. Toxicol.* **2015**,
642 *116* (3), 179–186. <https://doi.org/10.1111/bcpt.12342>.

- 643 (11) Kansy, M.; Senner, F.; Gubernator, K. Screening : Parallel Artificial Membrane
644 Permeation Assay in the Description Of. *J. Med. Chem.* **1998**, *41* (7), 1007–
645 1010.
- 646 (12) Artursson, P.; Palm, K.; Luthman, K. Caco-2 Monolayers in Experimental and
647 Theoretical Predictions of Drug Transport. *Adv. Drug Deliv. Rev.* **2012**, *64*
648 (SUPPL.), 280–289. <https://doi.org/10.1016/j.addr.2012.09.005>.
- 649 (13) Di, L.; Whitney-Pickett, C.; Umland, J. P.; Zhang, H.; Zhang, X.; Gebhard, D. F.;
650 Lai, Y.; Federico III, J. J.; Davidson, R. E.; Smith, R.; Reyner, E. L.; Lee, C.; Feng, B.;
651 Rotter, C.; Varma, M. V; Kempshall, S.; Fenner, K.; El-kattan, A. F.; Liston, T. E.;
652 Troutman, M. D. Development of a New Permeability Assay Using Low-Efflux
653 MDCKII Cells. *J. Pharm. Sci.* **2011**, *100* (11), 4974–4985.
654 <https://doi.org/10.1002/jps.22674>.
- 655 (14) Sarmento, B. *Concepts and Models for Drug Permeability Studies - Cell and*
656 *Tissue Based In Vitro Culture Models*, 1st Editio.; Woodhead Publishing, 2015.
- 657 (15) Lock, J. Y.; Carlson, T. L.; Carrier, R. L. Mucus Models to Evaluate the Diffusion
658 of Drugs and Particles. *Adv. Drug Deliv. Rev.* **2018**, *124*, 34–49.
659 <https://doi.org/10.1016/j.addr.2017.11.001>.
- 660 (16) Butnarusu, C.; Barbero, N.; Pacheco, D.; Petrini, P.; Visentin, S. Mucin Binding to
661 Therapeutic Molecules: The Case of Antimicrobial Agents Used in Cystic
662 Fibrosis. *Int. J. Pharm.* **2019**, *564* (January), 136–144.
663 <https://doi.org/10.1016/j.ijpharm.2019.04.032>.
- 664 (17) Norris, D. A.; Sinko, P. J. Effect of Size, Surface Charge, and Hydrophobicity on
665 the Translocation of Polystyrene Microspheres through Gastrointestinal
666 Mucin. *J. Appl. Polym. Sci.* **1997**, *63* (11), 1481–1492.
667 [https://doi.org/10.1002/\(SICI\)1097-4628\(19970314\)63:11<1481::AID-
668 APP10>3.0.CO;2-5](https://doi.org/10.1002/(SICI)1097-4628(19970314)63:11<1481::AID-APP10>3.0.CO;2-5).
- 669 (18) Boegh, M.; Baldursdóttir, S. G.; Müllertz, A.; Nielsen, H. M. Property Profiling of
670 Biosimilar Mucus in a Novel Mucus-Containing in Vitro Model for Assessment
671 of Intestinal Drug Absorption. *Eur. J. Pharm. Biopharm.* **2014**, *87* (2), 227–235.
672 <https://doi.org/10.1016/j.ejpb.2014.01.001>.
- 673 (19) Onnainty, R.; Usseglio, N.; Bonafé Allende, J. C.; Granero, G. Exploring a New
674 Free-Standing Polyelectrolyte (PEM) Thin Film as a Predictive Tool for Drug-
675 Mucin Interactions: Insights on Drug Transport through Mucosal Surfaces. *Int.*
676 *J. Pharm.* **2021**, *604* (March), 120764.
677 <https://doi.org/10.1016/j.ijpharm.2021.120764>.
- 678 (20) Grainger, C. I.; Greenwell, L. L.; Lockley, D. J.; Martin, G. P.; Forbes, B. Culture of

- 679 Calu-3 Cells at the Air Interface Provides a Representative Model of the Airway
680 Epithelial Barrier. *Pharm. Res.* **2006**, *23* (7), 1482–1490.
681 <https://doi.org/10.1007/s11095-006-0255-0>.
- 682 (21) Falavigna, M.; Klitgaard, M.; Brase, C.; Ternullo, S.; Škalko-Basnet, N.; Flaten, G.
683 E. Mucus-PVPA (Mucus Phospholipid Vesicle-Based Permeation Assay): An
684 Artificial Permeability Tool for Drug Screening and Formulation Development.
685 *Int. J. Pharm.* **2018**, *537* (1–2), 213–222.
686 <https://doi.org/10.1016/j.ijpharm.2017.12.038>.
- 687 (22) Pacheco, D. P.; Butnarasu, C. S.; Briatico Vangosa, F.; Pastorino, L.; Visai, L.;
688 Visentin, S.; Petrini, P. Disassembling the Complexity of Mucus Barriers to
689 Develop a Fast Screening Tool for Early Drug Discovery. *J. Mater. Chem. B*
690 **2019**, *7* (32), 4940–4952. <https://doi.org/10.1039/C9TB00957D>.
- 691 (23) Hentzer, M.; Teitzel, G. M.; Balzer, G. J.; Heydorn, A.; Molin, S.; Givskov, M.;
692 Parsek, M. R. Alginate Overproduction Affects *Pseudomonas Aeruginosa*
693 Biofilm Structure and Function. *J. Bacteriol.* **2001**, *183* (18), 5395–5401.
694 <https://doi.org/10.1128/JB.183.18.5395-5401.2001>.
- 695 (24) Leid, J. G.; Willson, C. J.; Shirtliff, M. E.; Hassett, D. J.; Parsek, M. R.; Jeffers, A. K.
696 The Exopolysaccharide Alginate Protects *Pseudomonas Aeruginosa* Biofilm
697 Bacteria from IFN- γ -Mediated Macrophage Killing. *J. Immunol.* **2005**, *175* (11),
698 7512–7518. <https://doi.org/10.4049/jimmunol.175.11.7512>.
- 699 (25) Bidmon, K.; Lieleg, O.; Berensmeier, S. An Optimized Purification Process for
700 Porcine Gastric Mucin with Preservation of Its Native Functional Properties.
701 *RSC Adv.* **2016**, *6*, 44932–44943. <https://doi.org/10.1039/C6RA07424C>.
- 702 (26) Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.;
703 Chang, Z.; Woolsey, J. DrugBank: A Comprehensive Resource for in Silico Drug
704 Discovery and Exploration. *Nucleic Acids Res.* **2006**, *34* (Database issue), 668–
705 672. <https://doi.org/10.1093/nar/gkj067>.
- 706 (27) Kim, S.; Chen, J.; Cheng, T.; Gindulyte, A.; He, J.; He, S.; Li, Q.; Shoemaker, B. A.;
707 Thiessen, P. A.; Yu, B.; Zaslavsky, L.; Zhang, J.; Bolton, E. E. PubChem in 2021:
708 New Data Content and Improved Web Interfaces. *Nucleic Acids Res.* **2021**, *49*
709 (D1), D1388–D1395. <https://doi.org/10.1093/nar/gkaa971>.
- 710 (28) Sharifian Gh., M. Recent Experimental Developments in Studying Passive
711 Membrane Transport of Drug Molecules. *Mol. Pharm.* **2021**.
712 <https://doi.org/10.1021/acs.molpharmaceut.1c00009>.
- 713 (29) Oriano, M.; Terranova, L.; Sotgiu, G.; Saderi, L.; Bellofiore, A.; Retucci, M.;
714 Marotta, C.; Gramegna, A.; Miglietta, D.; Carnini, C.; Marchisio, P.; Chalmers, J.

- 715 D.; Aliberti, S.; Blasi, F. Evaluation of Active Neutrophil Elastase in Sputum of
716 Bronchiectasis and Cystic Fibrosis Patients: A Comparison among Different
717 Techniques. *Pulm. Pharmacol. Ther.* **2019**, *59* (October), 1–6.
718 <https://doi.org/10.1016/j.pupt.2019.101856>.
- 719 (30) Chen, X.; Murawski, A.; Patel, K.; Crespi, C. L.; Balimane, P. V. A Novel Design of
720 Artificial Membrane for Improving the PAMPA Model. *Pharm. Res.* **2008**, *25*
721 (7), 1511–1520. <https://doi.org/10.1007/s11095-007-9517-8>.
- 722 (31) Teixeira, L. de S.; Chagas, T. V.; Alonso, A.; Gonzalez-alvarez, I.; Bermejo, M.;
723 Polli, J.; Rezende, K. R. Biomimetic Artificial Membrane Permeability Assay
724 over Franz Cell Apparatus Using Bcs Model Drugs. *Pharmaceutics* **2020**, *12*
725 (10), 1–16. <https://doi.org/10.3390/pharmaceutics12100988>.
- 726 (32) Sugano, K.; Takata, N.; Machida, M.; Saitoh, K.; Terada, K. Prediction of Passive
727 Intestinal Absorption Using Bio-Mimetic Artificial Membrane Permeation
728 Assay and the Paracellular Pathway Model. *Int. J. Pharm.* **2002**, *241* (2), 241–
729 251. [https://doi.org/10.1016/S0378-5173\(02\)00240-5](https://doi.org/10.1016/S0378-5173(02)00240-5).
- 730 (33) Artursson, P.; Bergström, C. A. S. Intestinal Absorption: The Role of Polar
731 Surface Area. *Drug Bioavailability*. May 27, 2003, pp 339–357.
732 <https://doi.org/https://doi.org/10.1002/3527601473.ch15>.
- 733 (34) Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High Throughput
734 Artificial Membrane Permeability Assay for Blood-Brain Barrier. *Eur. J. Med.*
735 *Chem.* **2003**, *38* (3), 223–232. [https://doi.org/10.1016/S0223-](https://doi.org/10.1016/S0223-5234(03)00012-6)
736 [5234\(03\)00012-6](https://doi.org/10.1016/S0223-5234(03)00012-6).
- 737 (35) Köllmer, M.; Mossahebi, P.; Sacharow, E.; Gorissen, S.; Gräfe, N.; Evers, D. H.;
738 Herbig, M. E. Investigation of the Compatibility of the Skin PAMPA Model with
739 Topical Formulation and Acceptor Media Additives Using Different Assay
740 Setups. *AAPS PharmSciTech* **2019**, *20* (2), 1–10.
741 <https://doi.org/10.1208/s12249-019-1305-3>.
- 742 (36) Matsson, P.; Kihlberg, J. How Big Is Too Big for Cell Permeability? *J. Med. Chem.*
743 **2017**, *60* (5), 1662–1664. <https://doi.org/10.1021/acs.jmedchem.7b00237>.
- 744 (37) Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Structure-Brain Exposure
745 Relationships. *J. Med. Chem.* **2006**, *49* (17), 12–14.
746 <https://doi.org/10.1021/jm060379l>.
- 747 (38) Shityakov, S.; Neuhaus, W.; Dandekar, T.; Förster, C. Analysing Molecular Polar
748 Surface Descriptors to Predict Blood-Brain Barrier Permeation. *Int. J. Comput.*
749 *Biol. Drug Des.* **2013**, *6* (1–2), 146–156.
750 <https://doi.org/10.1504/IJCBDD.2013.052195>.

- 751 (39) Tang, B.; Wang, J.; Wang, Q.; Xiao, Y.; Huang, Y.; Liao, X.; Li, H. Calcium(II)-
752 Naproxen Complex: Synthesis, Characterization, and Interaction with Human
753 Serum Albumin. *Spectrosc. Lett.* **2016**, *49* (6), 404–412.
754 <https://doi.org/10.1080/00387010.2016.1174137>.
- 755 (40) Atassi, F.; Mao, C.; Masadeh, A. S.; Byrn, S. R. Solid-State Characterization of
756 Amorphous and Mesomorphous Calcium Ketoprofen. *J. Pharm. Sci.* **2010**, *99*
757 (9), 3684–3697. <https://doi.org/10.1002/jps.21925>.
- 758 (41) Ogiso, T.; Ito, Y.; Iwaki, M.; Atago, H. Absorption of Indomethacin and Its
759 Calcium Salt through Rat Skin: Effect of Penetration Enhancers and
760 Relationship between in Vivo and in Vitro Penetration. *J. Pharmacobiodyn.*
761 **1986**, *9*, 517–525.
- 762 (42) Mandel, I. D.; Eriv, A.; Kutscher, A.; Denning, C.; Thompson, R. H.; Kessler, W.;
763 Zegarelli, E. Calcium and Phosphorus Levels in Submaxillary Saliva. *Clin.*
764 *Pediatr. (Phila)*. **1969**, *8* (3), 161–164.
765 <https://doi.org/10.1177/000992286900800308>.
766